Upcoming Events
Events at a glance
- Grant writing workshop – ECRs and PhD Students in Data Science and AI
- Cambridge New Theraputics Forum (CamNTF)
- 2026 Milner Consortium Call
Grant writing workshop – ECRs and PhD Students in Data Science and AI
A keynote presentation will be delivered by Dr Mia Sato Tackney, MRC Biostatistics Unit. Hear her story from an awardee of a C2D3 Seed Fund in 2023 to a NIHR Advanced Fellowship in 2025.
Finally we will have a panel discussion from four leading academics, to hear their thoughts on what makes a successful funding application, common pitfalls, and strategies for ensuring your writing is persuasive.
Programme
Registration, tea and coffee
Welcome: Professor Zoe Kourtzi, Department of Psychology & Co-Chair C2D3
Elevator pitch practice
Keynote: Success! From C2D3 Seed Fund to Fellowship
- Dr Mia Sato Tackney, MRC Biostatistics Unit, NIHR Advanced Fellow (2025-2030)
Panel discussion: Mastering the art of applications
- Chair: Professor Zoe Kourtzi
- Professor Alexandra Brintrup, Institute for Manufacturing
- Dr Alexis Litvine, Faculty of History
- Dr Anna Moore Winter, Associate Professor, Department of Psychiatry, UKRI Future Leaders Fellow
- Professor Qingyuan Zhao, Department of Pure Mathematics and Mathematical Statistics, Associate Faculty of the Cambridge Centre for AI in Medicine (CCAIM).
Discussion and networking
Registration
Registration is essential and closes Wed 14th January at 17:00, please see the notes below about entry to the venue.
Cambridge New Theraputics Forum (CamNTF)
Theo Chalmers Lecture Theatre, School of Clinical Medicine, Hills Road, Cambridge, CB2 0SP
21st January 2026
18:00 - 20:00
Speakers:
Nataly Hastings, CEO, Cellestial Health, Cambridge
Validating a novel drug target in Parkinson's: where to begin?
Simon Stott, Director of Research, Cure Parkinson's, London
Developing a new therapy - understanding positioning: A case study in Parkinson's.
Julia Greenland, Neurology Registrar, Addenbrooke's Hospital, Cambridge.
Immunosuppression for Parkinson's disease?: Learning points from AZA-PD, a
randomised controlled trial of azathioprine.
Jonathan Benn, TRIMTECH Therapeutics, Cambridge
Aggregation State Selective Protein Degradation: A Novel Therapeutic Modality for Neurodegenerative Diseases.
Event registrations will open shortly please visit the website
2026 Milner Consortium Call
22nd January 2026
Online Webinar - 10:00
About the Consortium Call
The pharma partners in the Milner Therapeutics Consortium have been working together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing to funded pilot or longer-term collaborations (2-3 years) and are expected to lead to joint publications with the company partners.
The Milner Therapeutics Consortium Call will launch its sixth call for research proposals on 12 January. Please join the Zoom Q&A webinar on 22 January to find out more and ask questions about the call for proposals.